Corporate Philanthropy - Best Practices at Novartis AG
|
|
ICMR HOME | Case Studies Collection
Case Details:
Case Code : BECG063
Case Length : 23 Pages
Period : 2000-06
Organization : Novartis AG, Novartis Foundation for Sustainable
Pub Date : 2006
Teaching Note : Available
Countries : Switzerland
Industry : Pharmaceutical
To download Corporate Philanthropy - Best Practices at Novartis AG case study (Case Code:
BECG063) click on the button below, and select the case from the list of available cases:
OR
Buy With PayPal
|
Price:
For delivery in electronic format: Rs. 500 ;
For delivery through Shipping & Handling Charges extra: Rs. 500 +Shipping & Handling Charges extra
» Business Ethics Case Studies
» Case Studies Collection
» ICMR Home
» View Detailed Pricing Info
» How To Order This Case
» Business Case Studies
» Case Studies by Area
» Case Studies by Industry
» Case Studies by Company
Please note:
This case study was compiled from published sources, and is intended to be used as a basis for class discussion. It is not intended to illustrate either effective or ineffective handling of a management situation. Nor is it a primary information source.
Chat with us
Please leave your feedback
|
|
<< Previous
Introduction Contd,..
|
The Novartis Foundation, in association with international partners like the
World Health Organization3 (WHO), the
United Nations4 (UN) and developmental
institutions, worked toward promoting economic, cultural, and social human
rights in developing countries.
The Foundation also worked to reduce health and poverty-related problems of the
Third World. Another main task of the Novartis Foundation was to serve as a
bridge between Novartis and the community consisting of developmental
institutions, non-governmental organizations (NGOs), the private sector, and
government institutions.
|
|
In a scenario where there was a growing demand for corporates to play a
proactive role in dealing with the problems of society, the Novartis
Foundation was playing its part in dealing with poverty and disease in Third
World countries and was guided by a clear vision to do so (Refer Exhibit III
for Vision, Mission, and Objectives of the Novartis Foundation).
|
|
According
to Dr. Kalus M. Leisinger (Leisinger), who had been President and CEO of
the Novartis Foundation since the year 2002, "For many years we have had
our leprosy program, we now have our malaria program, we have our
tuberculosis donation, and we offer our employees throughout the
developing world free diagnosis and treatment for HIV/AIDS, TB, and
malaria.
In addition, we have founded a new research institute in Singapore that
exclusively carries out "pro bono"research on a non-profit making
basis, such as for tuberculosis and dengue fever. I am very proud of
this and I think we have given a clear signal with our initiatives."5 |
Excerpts >>
|
|
